Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
OncoSil Medical Ltd ( (AU:OSL) ) just unveiled an announcement.
OncoSil Medical Ltd reported a significant increase in revenue by 126.6% to $1,170,793 for the year ending June 30, 2025, despite a 26.7% rise in losses to $15,099,844. The company did not declare any dividends during this period. A notable decrease in net tangible assets per ordinary security was observed, dropping from 57.32 cents to 21.86 cents. The upcoming Annual General Meeting is scheduled for November 19, 2025, where key decisions regarding the company’s future direction will be discussed. The financial statements have been audited, with an unmodified opinion issued, although a material uncertainty related to going concern was noted.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
More about OncoSil Medical Ltd
OncoSil Medical Ltd operates within the medical industry, focusing on developing innovative medical products. The company is primarily engaged in the production and commercialization of its proprietary OncoSil device, which is used for the treatment of pancreatic cancer. OncoSil Medical Ltd aims to enhance cancer treatment options and improve patient outcomes.
Average Trading Volume: 41,913
Technical Sentiment Signal: Sell
Current Market Cap: A$21.65M
See more data about OSL stock on TipRanks’ Stock Analysis page.